Optic choroid disorder

This Phase 3 trial tests a new drug called belzupacap sarotalocan (AU-011) for people with small choroidal melanoma or suspicious spots in the eye. The drug is injected into the eye and activated by a laser to target cancer cells. The study compares it to a sham (fake) procedure …

This phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…

This early-phase trial tests a single injection of a gene therapy called RTx-015 in 10 adults with retinitis pigmentosa or choroideremia, two inherited conditions that cause vision loss. The therapy delivers a gene that makes retinal cells produce a light-sensitive protein, poten…

This early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injectio…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study follows 46 people with gyrate atrophy, a rare genetic condition that causes vision loss, over 4 years. Researchers measure ornithine levels in the blood and track changes in the retina using eye scans and photos. The goal is to learn how the disease progresses under st…

This registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving ne…